This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

This study has been completed.
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Information provided by:
Dana-Farber Cancer Institute Identifier:
First received: November 8, 2005
Last updated: March 9, 2011
Last verified: March 2011
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.

Condition Intervention Phase
Leukemia, Myelocytic, Acute Acute Lymphocytic Leukemia Drug: 9-Aminocamptothecin (9-AC) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Study of 9-AC in Refractory Leukemia

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia. [ Time Frame: Years ]

Secondary Outcome Measures:
  • To analyze the pharmacokinetics in these patients. [ Time Frame: years ]

Estimated Enrollment: 52
Study Start Date: January 1995
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Detailed Description:
  • The treatment patients will receive involves a continuous infusion of 9-AC intravenously for a 72 hour period. Since we are unsure of the safest and most effective dose, successive groups of 4-7 patients will receive larger doses of this drug until the largest dose given safely is established.
  • Prior to the start of therapy a bone marrow aspirate and biopsy will be taken for diagnostic and research purposes. A bone marrow exam will be repeated at 48 hours in order to determine the effects of 9-AC on leukemic cells in the bone marrow. A bone marrow scan will also be performed 14 days after the start of therapy to assess response.
  • Frequent blood testing will be done throughout treatment, including blood samples to determine the levels of the 9-AC in the blood.
  • Treatment could be stopped prematurely if any of the following occur: 1) drug causes severe side effects, 2) the drug does not control the leukemia, or 3) the doctors or the patient feel that it is no longer in the patients best interest to receive this therapy.
  • Approximately 7 days after the conclusion of the 9-AC infusion, it is likely that the patient's blood counts will be low and will require support with antibiotics, red cell transfusions and platelet transfusions.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase
  • Central venous access
  • ECOG performance status of less than or equal to 2
  • Bilirubin < 1.3
  • SGOT < 2 x ULN
  • Alkaline phosphatase < 2 x ULN
  • Creatinine < 1.5

Exclusion Criteria:

  • Undergone bone marrow transplantation
  • Uncontrolled infection
  • Other active malignancy
  • HIV positivity
  • Serious medical or psychiatric illness
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00251368

United States, Massachusetts
Massachusetts General Hosptial
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Principal Investigator: Richard Stone, MD Dana-Farber Cancer Institute
  More Information Identifier: NCT00251368     History of Changes
Other Study ID Numbers: 94-115
Study First Received: November 8, 2005
Last Updated: March 9, 2011

Keywords provided by Dana-Farber Cancer Institute:
refractory leukemia
relapsed leukemia

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017